Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) and Sagimet Biosciences (NASDAQ:SGMT – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.
Earnings & Valuation
This table compares Kiniksa Pharmaceuticals International and Sagimet Biosciences”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kiniksa Pharmaceuticals International | $677.56 million | 9.30 | $59.01 million | $0.97 | 83.29 |
| Sagimet Biosciences | $2.00 million | 309.25 | -$51.04 million | ($1.28) | -7.77 |
Kiniksa Pharmaceuticals International has higher revenue and earnings than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and price targets for Kiniksa Pharmaceuticals International and Sagimet Biosciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kiniksa Pharmaceuticals International | 0 | 1 | 8 | 0 | 2.89 |
| Sagimet Biosciences | 2 | 1 | 9 | 0 | 2.58 |
Kiniksa Pharmaceuticals International presently has a consensus price target of $93.14, suggesting a potential upside of 15.29%. Sagimet Biosciences has a consensus price target of $26.63, suggesting a potential upside of 167.68%. Given Sagimet Biosciences’ higher probable upside, analysts plainly believe Sagimet Biosciences is more favorable than Kiniksa Pharmaceuticals International.
Insider & Institutional Ownership
53.9% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Comparatively, 11.5% of Sagimet Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Kiniksa Pharmaceuticals International and Sagimet Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kiniksa Pharmaceuticals International | 9.59% | 13.65% | 10.09% |
| Sagimet Biosciences | N/A | -31.96% | -30.57% |
Volatility and Risk
Kiniksa Pharmaceuticals International has a beta of 0.04, indicating that its stock price is 96% less volatile than the S&P 500. Comparatively, Sagimet Biosciences has a beta of 3.46, indicating that its stock price is 246% more volatile than the S&P 500.
Summary
Kiniksa Pharmaceuticals International beats Sagimet Biosciences on 9 of the 14 factors compared between the two stocks.
About Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.
About Sagimet Biosciences
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Receive News & Ratings for Kiniksa Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.
